Kramer Laboratories, Inc (Kramer) has announced its acquisition of Nizoral.
Sold in North America and Latin America, Nizoral is an anti-dandruff shampoo brand from Pharmaceutica NV (a Johnson & Johnson company). Kramer is a portfolio company of healthcare-focused private equity firm Avista Capital Partners, and consumer healthcare-focused private investment group Dana Holdings.
“We are delighted to add Nizoral, an iconic OTC brand, to the Kramer portfolio. With over a 25-year history, Nizoral is one of the most widely-recognized and highly-trusted brands in therapeutic hair care,” said Rick Kornhauser, Kramer CEO. “This acquisition also significantly enhances our financial profile, adding meaningful scale, growth and profitability to our company. We look forward to building upon Nizoral's strong brand heritage and continuing to grow the brand through investment and brand support.”
Added David Burgstahler, president and co-managing partner of Avista, “This is a transformative acquisition for Kramer, one that not only adds an exceptional brand to the portfolio but also establishes Kramer as a leading OTC consumer healthcare platform of scale. We are excited about Kramer's future prospects and are committed to supporting the company's continued development and expansion.”